Novo Nordisk Sheds Autoimmune Portfolio to BMS
Wednesday, March 25, 2015
Under the deal, financial details of which have not been disclosed, Bristol-Myers Squibb will acquire an exclusive global license to a discovery biologics research programme focused on modulating the immune system as a therapy for autoimmune diseases.
For BMS, this deal slots neatly into its own long-standing research into immunoscience, a core therapeutic area for the company that has a number of drug candidates in development to target immune-mediated diseases.
Novo is currently the world's number one insulin maker but is facing an encroachment on its market share as new insulin products from Sanofi, coupled with cheaper biosimilar drugs on the horizon, will cut the Danish firm's leading status.